Ambrisentan - Noorik Biopharmaceuticals

Drug Profile

Ambrisentan - Noorik Biopharmaceuticals

Alternative Names: N-003

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Noorik Biopharmaceuticals
  • Class Phenylpropionates; Pyridazines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatorenal syndrome

Highest Development Phases

  • Phase II Hepatorenal syndrome
  • Preclinical Delayed graft function

Most Recent Events

  • 08 Jun 2018 Noorik Biopharmaceuticals terminates phase II trial in Hepatorenal syndrome in Greece, before June 2018 (IV) (EudraCT2016-002226-36)
  • 22 Nov 2016 Preclinical trials in Delayed graft function (Prevention) in Greece (unspecified route) before November 2016 (Noorik Biopharmaceuticals website, November 2016)
  • 22 Nov 2016 Ambrisentan is available for licensing as of 22 Nov 2016. http://www.noorik.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top